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Editorial on the Research Topic
Biological Mechanism-Based and Patient-CenteredManagement of Cancer-Related Symptoms
and Syndromes
In recent years, full recovery rates for cancer patients significantly increased and mean survival
improved. Moreover, chronicization of cancer disease and concerns about aggressive care close
to the end-of-life raised the awareness of better risk-benefit balancing. As a result, patients are
increasingly aware of quality of life (QoL) issues, and physicians need to find the right balance
between cancer treatment and patient well-being. Notably, for most tumors, especially at advanced
stages, the concept of cancer as a multidimensional systemic disease replaced the idea of cancer as
an organ-confined disease. A new way of design of antineoplastic treatments aiming to patient-
centered outcomes including clinical benefit, symptom control, and psycho-social well-being is
needed. For this scope, the notion of simultaneous care, i.e., early integration of palliative care
into the cancer disease trajectory, must be pursued in clinical practice.
Cancer-associated symptoms, such as anorexia, fatigue, depression, and syndromes such as
cachexia, appear more frequently in advanced stages but they actually start with the onset of cancer.
Therefore, any antineoplastic therapeutic approach should ideally be planned within the context
of “best supportive care,” including optimal symptom management and careful psychosocial and
spiritual counseling (Madeddu et al., 2015). However, to date the exact biological mechanisms of
cancer-associated symptoms and their specific treatment have not been well defined yet.
This Research Topic aimed to gain the knowledge of the pathophysiology of cancer symptoms
and syndromes to implement a proactive structured evaluation and targeted interventions. We
included just some significant conditions, namely anorexia, weight loss/cachexia, and anemia that
are very important for patient suffering, although yet unmeet concerns in clinical practice. The final
aim is to develop a model, which could be applied also to other symptoms or syndromes.
This Topic provides significant contributions in the issue of cancer-related muscle wasting and
cachexia pathogenesis and treatment. Interestingly, Barreto et al. analyzed the proteomic signature
of muscle wasting induced by different conditions (i.e., cancer cachexia and chemotherapy). They
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showed a significant activation mainly of the pathways
that regulate nucleotide and fatty acid metabolism, ATP
synthesis, muscle and heart function, and ROS scavenging. This
evidence has important translational implications and supports a
combination strategy as the potentially most effective treatment
for cachexia. This evidence is further supported by Pin et al.
which suggested that inhibiting a single proteolytic pathway is
not a good strategy to contrast cancer-induced muscle wasting.
In fact, they showed that the inhibition of the Ca2+-dependent
proteases did not change body weight loss and muscle wasting in
some animal experimental models of cancer cachexia.
As a consequence of changes in body composition and energy
metabolism, as well as of treatment-related toxicities, advanced
cancer patients very often show a decreased tolerance to exercise
and reduced levels of physical activity. Marmonti et al. present a
model of bed-rest induced muscle wasting, demonstrating how
inactivity may contribute to muscle atrophy associated with a
significant decline in muscle mass and force, as well as bone
mass loss. Similarly, Bonetto et al. demonstrated that bone loss
is associated with tumor growth in two experimental models of
colorectal cancer cachexia (HT-29, and ApcMin/+).
A fundamental step in establishing an effective targeted
supportive care of cancer symptoms is represented by their
structured multidimensional evaluation. Argilés et al. presents
the validation of the new tool Cachexia Score (CASCO) and its
shorten version miniCASCO, for the diagnosis and numerical
staging of cancer cachexia in different level of severity.
One of the most frequent and clinically relevant signs of
advanced stage cancer patients is cancer-related anemia (CRA).
The review by Madeddu et al. is focused on the main and novel
mechanisms involved in the multifactorial pathogenesis of CRA
and provides useful insights for the development of an effective
mechanism-based approach, which may be able to promote a
relevant amelioration of patients’ quality of life.
During the last years, it has become very clear that a
combination of nutrition, nutraceuticals, and drugs is a much-
preferred therapeutic approach to fight against cancer cachexia.
In the present Research Topic different therapeutic approaches
have been proposed. Blauwhoff-Buskermolen et al. showed in
a population of advanced non-small-cell lung cancer patients
that those with anorexia (one of the main features of cachexia)
had significantly higher ghrelin levels compared to those without
anorexia. Indeed, ghrelin plays an important orexigenic role
by stimulating the production of orexigenic neurons such as
neuropeptide Y. Then, anorectic/cachectic cancer patients can
benefit from a treatment with a ghrelin receptor agonist (Garcia
et al., 2013; Temel et al., 2016). Interleukin-6 (IL-6) is the main
proinflammatory cytokines involved in the etiopathogenenesis
of the main symptoms and syndromes of advanced cancer,
including CRA (Macciò et al., 2005) and cachexia (Zimmers et al.,
2016). Consistently, IL-6 inhibitors obtained promising results in
the treatment of cachexia and related symptoms (Bayliss et al.,
2011; Bekaii-Saab et al., 2011; Prado et al., 2012). In our topic,
Au et al. investigated the potential mechanisms of Selumetinib
(mitogen-activated protein/extracellular signal-regulated kinase
(MEK) inhibitor) in Lewis lung carcinoma, an experimental
animal model of cancer cachexia. Selumetinib reduced tumor
mass and circulating and tumor IL-6, but did not preserve
muscle mass. Another strategy is discussed by Molfino et al. they
showed that a dietary supplementation with docosahexaenoic
acid (DHA) was associated with increased DHA levels and
omega-3 index in red blood cells membranes of breast cancer
patients.
We hope that the present Research Topic could contribute a
greater insight to enable earlier andmore effective supportive and
palliative care for cancer patients. In fact, although traditional
cornerstones, such as diagnosis, staging, and anticancer
treatment will continue to play a crucial role, the knowledge
of the biological specificity of cancer-associated symptoms
should be considered a central issue by the multidisciplinary
team to optimize a patient-focused care. We are awareness that
such multidimensional personalized approach should include
also the assessment of the psychosocial and spiritual domains,
which can help patients to develop personal priorities regarding
relationships, religious and spiritual beliefs, deal with the urgency
of resolving conflicts, and achieve personally meaningful goals.
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